Antonio Gonzalez Martín, B. Slomovitz, K. Fujiwara, E. Kalbacher, A. Bagameri, S. Ghamande, Jung-Yun Lee, S. Banerjee, F.C. Maluf, Domenica Lorusso, K. Yonemori, E. Nieuwenhuysen, Luis Manso Sánchez, L. Woelber, A.M. Westermann, A. Covens, E. Whalley, Melinda Siew Leng Teng, I. Soumaoro, I. Vergote
{"title":"237 InnovaTV 301/ENGOT-Cx12/GOGG-3057:一项针对2L或3L复发性或转移性宫颈癌的替索单抗维多汀与研究者选择的化疗方案的全球性、随机、开放标签3期研究","authors":"Antonio Gonzalez Martín, B. Slomovitz, K. Fujiwara, E. Kalbacher, A. Bagameri, S. Ghamande, Jung-Yun Lee, S. Banerjee, F.C. Maluf, Domenica Lorusso, K. Yonemori, E. Nieuwenhuysen, Luis Manso Sánchez, L. Woelber, A.M. Westermann, A. Covens, E. Whalley, Melinda Siew Leng Teng, I. Soumaoro, I. Vergote","doi":"10.1136/ijgc-2024-esgo.7","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"71 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"237 InnovaTV 301/ENGOT-Cx12/GOG-3057: a global, randomized, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in 2L Or 3L recurrent or metastatic cervical cancer\",\"authors\":\"Antonio Gonzalez Martín, B. Slomovitz, K. Fujiwara, E. Kalbacher, A. Bagameri, S. Ghamande, Jung-Yun Lee, S. Banerjee, F.C. Maluf, Domenica Lorusso, K. Yonemori, E. Nieuwenhuysen, Luis Manso Sánchez, L. Woelber, A.M. Westermann, A. Covens, E. Whalley, Melinda Siew Leng Teng, I. Soumaoro, I. Vergote\",\"doi\":\"10.1136/ijgc-2024-esgo.7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517822,\"journal\":{\"name\":\"Oral Sessions\",\"volume\":\"71 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Sessions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-esgo.7\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
237 InnovaTV 301/ENGOT-Cx12/GOG-3057: a global, randomized, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in 2L Or 3L recurrent or metastatic cervical cancer